Related by context. All words. (Click for frequent words.) 70 mm Hg systolic 69 mmHg diastolic 69 -#.# mm Hg 68 diastolic BP 68 mmHg systolic 68 #.#/#.# mm Hg [001] 66 systolic BP 66 #/#mmHg 66 mmHg 65 mm Hg diastolic 65 systolic blood pressures 64 baseline serum creatinine 64 #.#/#.# mm Hg [003] 64 #mmHg [001] 64 #.#mmHg 63 normotensive 63 total cholesterol triglycerides 63 diastolic blood pressures 62 nondiabetic patients 62 mL/min/#.# m 2 61 HbA 1c 61 glycosylated hemoglobin HbA1c 61 -#.# mg dL [001] 61 mm Hg 61 fasting plasma glucose FPG 61 hypertensives 61 serum creatinine levels 60 -#.# mg dL [002] 60 supine systolic 60 pulmonary capillary wedge 60 #.#mg/dL 60 #mmHg [002] 60 baseline HbA1c 60 systolic diastolic 59 SBP DBP 59 #mm Hg 59 fasting glucose 59 Systolic 59 nicardipine 59 #.#/#.# mmHg [001] 59 Diastolic 59 serum triglycerides 59 glycated hemoglobin HbA1c 59 mmol liter 59 benazepril 59 neutrophil counts 59 rizatriptan 59 systolic diastolic blood 59 Intraocular pressure 59 -#.# mmHg 59 alanine aminotransferase 58 #mg/day [001] 58 elevated fasting glucose 58 echocardiographic parameters 58 sUA 58 aspartate aminotransferase AST 58 μg L 58 LDL cholesterol HDL cholesterol 58 glomerular filtration 58 urinary sodium excretion 58 REYATAZ r arm 58 β blockers 58 HDL cholesterol triglycerides 58 leucopenia 58 cells uL 58 serum urate levels 58 labetalol 58 intima media thickness 58 creatinine ratio 58 lispro 58 baseline A1C 58 tirofiban 58 #.#mmol L [002] 58 Fasting glucose 57 triglycerides TG 57 oxycodone CR 57 highest tertile 57 Hb A1C 57 HbA 1c levels 57 serum cortisol 57 elevated hsCRP 57 mmol l 57 unfractionated heparin UFH 57 mcg BID 57 aspartate aminotransferase 57 serum ferritin 57 albumin excretion rate 57 candesartan cilexetil 57 adiponectin concentrations 57 lumbar spine BMD 57 4mg/kg 57 plasma renin activity 57 elevated serum creatinine 57 pg ml 57 nonsignificant difference 57 P = .# 57 angiotensin converting enzyme inhibitors 57 Non Responders 57 proteinuria 57 irbesartan 57 nondiabetics 57 Acetate Rectal Suppositories 57 angiotensin II receptor blockers 57 umol L 56 Flu Cy 56 HbA1c levels 56 log# copies mL 56 Cmax 56 lowest tertile 56 binary restenosis 56 serum potassium 56 pooled comparator 56 Fasting plasma glucose 56 quetiapine risperidone 56 HbA1C levels 56 adjunctive placebo 56 NSTE ACS 56 #.#mmol L [001] 56 biphasic insulin aspart 56 #ug [001] 56 serum urate 56 lactate dehydrogenase LDH 56 diastolic pressures 56 creatinine levels 56 normal ULN 56 fasting plasma glucose 56 fasting insulin 56 serum homocysteine 56 fasting glucose levels 56 oxycodone IR 56 urinary N telopeptide 56 g dl 56 NHANES III 56 glucose insulin 56 HOMA IR 56 pulmonary arterial 56 plasma homocysteine 56 deep venous thromboses 56 x ULN 56 fasting serum 56 #mg/dL [001] 56 LDL triglycerides 56 alanine aminotransferase ALT 56 diastolic blood pressure 56 mg TID 55 HBeAg negative patients 55 arterial thromboembolic events 55 glulisine 55 aspirin clopidogrel 55 hydroxyvitamin D concentrations 55 nmol liter 55 apolipoprotein B 55 comparator arm 55 triacylglycerol concentrations 55 Fibrates 55 blood urea nitrogen 55 mL/min/#.# m2 55 #OHD levels 55 baseline Hb 55 mg BID dose 55 fasting triglyceride levels 55 triglyceride TG 55 PaO 2 55 confidence interval #.#-#.# 55 statin monotherapy 55 moderate renal impairment 55 hyperlipidaemia 55 ‰ ¥ 55 HDL Cholesterol 55 -#.# ± [002] 55 specific antigen PSA 55 glycaemia 55 μg mL 55 relapsed MM 55 serum magnesium 55 -#.# log# copies mL 55 XIENCE V PROMUS Stent 55 fraction LVEF 55 mmHg p = 55 #.#ng/ml 55 MADRS score 55 plasma glucose levels 55 Hypertensive Patients 55 EURIDIS 55 Fasting blood glucose 55 triglyceride concentrations 55 elevated ALT 55 BENICAR 55 ramipril 55 mIU ml 55 + PH# 55 systolic dysfunction 55 plus GP IIb 55 hip BMD 55 racemic albuterol 55 flutamide 55 Hemoglobin A1c 55 PREZISTA r arm 55 morphometric vertebral fractures 55 femoral neck BMD 55 hematopoietic cancers 55 urinary albumin 55 ng dL 55 AST ALT 55 cholesterol LDL C 55 sodium nitroprusside 55 Atherosclerotic 55 lopinavir r arm 55 pg mL 55 angiotensin converting enzyme 55 hyperlipidemic 55 CVD mortality 55 serum lipid levels 54 p = NS 54 plasma urate 54 impaired glucose metabolism 54 % CI #.#-#.# [003] 54 headache nasopharyngitis 54 mEq L 54 SGPT 54 PROCTOCORT ® Suppository Hydrocortisone 54 transferrin saturation 54 dapagliflozin plus 54 undetectable viral 54 #mg/day [002] 54 dalteparin 54 elevated creatinine 54 Levels Linked 54 ACE Inhibitor 54 serum uric acid 54 lopinavir r 54 pmol L 54 μg liter 54 acarbose 54 pT3 54 hemodilution 54 NPH insulin 54 TAXUS p value 54 Antihypertensive 54 mg q#h 54 antihypertensive therapy 54 Primary endpoints 54 CR nPR 54 nadolol 54 CK # plasma concentrations 54 Relapsing Remitting Multiple Sclerosis 54 hypophosphatemia 54 DAS# scores 54 elevated LDL cholesterol 54 LV ejection fraction 54 serum leptin 54 mg d 54 urinary oxalate 54 FDA defined valvulopathy 54 diuretic chlorthalidone 54 plasma folate 54 plus glycoprotein IIb 54 CK MB 54 PRADAXA #mg 54 thiazide diuretics 54 homocysteine concentrations 54 mg qd 54 BENICAR HCT 54 elevated uric acid 54 abnormal lipid levels 54 Ramipril 54 folate concentrations 54 mcg QD 54 tHcy 54 total cholesterol LDL 54 ATACAND 54 achieved sustained virological 54 hemoglobin A1c HbA1c 54 atazanavir ritonavir 54 vitreous floaters 54 % CI #.#-#.# [007] 54 serum IGF 54 primary aldosteronism 54 Subgroup analysis 54 nonobese 54 Postmenopausal Women 54 UACR 54 abdominal adiposity 54 CrCl 54 ritonavir boosted 54 hemoglobin A1c levels 54 SGOT 54 Pooled Analysis 54 leukopenia 54 recurrent DVT 54 aminotransferases 54 mg RDEA# 54 Hypertensive 54 hematological parameters 54 lispro alone 54 recurrent venous thromboembolism 54 % CI #.#-#.# [008] 54 glycated hemoglobin 54 confidence intervals CIs 54 recurrent UTI 54 systolic blood pressure 54 Mg Uk 54 systolic 54 RLAI 54 % Confidence Interval 53 CI -#.# 53 #mg BID [003] 53 Index CDAI 53 -#.# log# 53 lipid lowering agents 53 arterial thickening 53 urine albumin 53 leukocyte count 53 Demonstrated Significant 53 albumin excretion 53 serum PSA 53 plasma triglycerides 53 infliximab monotherapy 53 Vildagliptin 53 left ventricular hypertrophy 53 ischemia driven 53 lipid concentrations 53 hydroxymethyl coenzyme 53 ng dl 53 uM 53 mU liter 53 protein excretion 53 Serum creatinine 53 bezafibrate 53 hours postdose 53 titrated glipizide 53 mcg mL 53 biochemical relapse 53 affective psychosis 53 colesevelam 53 sUA levels 53 valsartan 53 #mg/dl 53 colorectal adenoma 53 baseline LDH 53 glycosylated hemoglobin 53 albuminuria 53 doxorubicin cyclophosphamide 53 ALT elevation 53 fasting plasma 53 #mg/dL [002] 53 serum CRP 53 TT genotype 53 μg kg 53 elevated troponin 53 oral antidiabetes 53 eosinophil count 53 dyslipidaemia 53 budesonide pMDI 53 nitroprusside 53 chlorthalidone 53 Symptom severity 53 efavirenz EFV 53 serum lipids 53 definite stent thrombosis 53 nasopharyngitis headache 53 hypercholesterolaemia 53 thienopyridines 53 dose atorvastatin 53 NMIBC 53 ACE Inhibitors 53 SCr 53 rs# [004] 53 mg/m2 dose 53 abacavir lamivudine 53 detemir 53 plasma renin 53 -#.# mmol L 53 C Reactive Protein 53 methotrexate monotherapy 53 mg dl 53 Hemodialysis Patients 53 coronary stenosis 53 aminotransferase levels 53 intact parathyroid hormone 53 baseline FEV 53 mg dL 53 abdominal pain flatulence 53 arterial oxygen saturation 53 salivary cortisol 53 mmol L 53 left ventricular systolic 53 pretreatment baseline 53 IIIa inhibitors 53 μg dL 53 poor metabolizers 53 insulin detemir 53 oral hypoglycemic 53 serum HBV DNA 53 p = .# [001] 53 Baseline characteristics 53 PASI scores 53 olmesartan 53 nondiabetic 53 epigastric pain 53 Crohn Disease Activity 53 NATRECOR R 53 nausea somnolence 53 HER2 expression 53 advanced adenoma 53 receiving ISENTRESS 53 nonfasting triglyceride levels 52 transaminases 52 maximal doses 52 milliliters mL 52 N telopeptide 52 chlorambucil 52 â ‰ ¥ 52 multivariable adjusted 52 mg BID 52 symptomatic VTE 52 diameter stenosis 52 elevated LDH 52 prospectively randomized 52 HbA1C 52 Complication rates 52 severe exacerbations 52 fractional shortening 52 advanced adenomas 52 FOLPI 52 NATRECOR ® 52 antihypertensives 52 Patients Receiving 52 lumbar spine bone 52 tertiles 52 placebo PBO 52 Cardiovascular Outcomes 52 metformin sulphonylurea 52 Thromboembolism 52 Apidra ® 52 serum phosphorous 52 endoscopic remission 52 adenoma recurrence 52 kg m² 52 dizziness nausea diarrhea 52 serum concentrations 52 tolterodine ER 52 prehypertensive 52 pulmonary artery pressure 52 paricalcitol 52 PCA3 scores 52 glycosylated hemoglobin levels 52 apnea hypopnea 52 LDL cholesterol concentrations 52 chills fever headache 52 urinary calcium 52 Key secondary endpoints 52 mIU L 52 CC genotype 52 nonfasting 52 mild renal insufficiency 52 plasma lipids 52 Unfractionated Heparin 52 kaempferol 52 tHcy concentrations 52 Toxicities 52 cerebral infarctions 52 elevated transaminases 52 Pharmacokinetic parameters 52 glipizide plus 52 creatinine clearance 52 nmol 52 0mg 52 density lipoprotein cholesterol 52 BMI ≥ 52 Exacerbation 52 serum prostate 52 Secondary efficacy endpoints 52 cTnI 52 saline placebo 52 Heart Failure Patients 52 prolactin levels 52 Endothelial Function 52 extrapyramidal symptoms 52 Insulin sensitivity 52 glycated hemoglobin levels 52 serum testosterone 52 preoperative PSA 52 salivary flow 52 Y BOCS 52 active comparator 52 diastolic hypertension 52 glomerular filtration rate 52 NSTEMI 52 Randomized controlled 52 symptomatic intracranial 52 methylmalonic acid 52 ABPM 52 atherogenic dyslipidemia 52 CDAI score 52 lipid lowering medications 52 creatine phosphokinase 52 5-FU/LV 52 eplerenone 52 mean baseline A1C 52 aldosterone antagonist 52 Wistar rats 52 Albuminuria 52 placebo dexamethasone 52 HLA DR 52 #.#mg l [001] 52 antihypertensive medications 52 ejection fractions 52 μmol L 52 Lipitor #mg 52 polyp recurrence 52 constipation dizziness 52 achieved ACR# 52 NYHA functional class 52 mmol 52 aged ≥ 52 serum phosphate levels 52 HbA1c 52 pCR 51 headache abdominal pain 51 oral hypoglycemic agents 51 serum estradiol 51 nausea photophobia 51 hypercalciuria 51 ß blockers 51 REMICADE monotherapy 51 creatine kinase 51 multivariate adjustment 51 nonfasting triglycerides 51 mg simvastatin 51 HBeAg seroconversion 51 NovoLog ® Mix 51 serum triglyceride 51 Poorly Controlled 51 bortezomib refractory 51 systemic corticosteroid 51 rimonabant #mg 51 NIDDM 51 hyperphenylalaninemia HPA due 51 natriuretic peptides 51 Triglyceride levels 51 serum parathyroid hormone 51 posttreatment 51 anemia hemoglobin 51 Ambulatory Blood Pressure 51 Sprague Dawley rats 51 LVEF 51 desvenlafaxine succinate 51 hsCRP levels 51 T2DM 51 PCWP 51 dose clopidogrel 51 HER2 amplification 51 mcg linaclotide 51 receiving concomitant corticosteroids 51 headache nausea diarrhea 51 ug kg 51 SSRI citalopram 51 DAS# CRP 51 Subgroup Analysis 51 prospectively stratified 51 injectable emulsion 51 % CI #.#-#.# [006] 51 erythrocyte sedimentation rate 51 thyrotropin levels 51 Lantus ® 51 Thiazolidinediones 51 laboratory abnormalities 51 plasma glucose 51 primary hypercholesterolemia 51 metformin monotherapy 51 serum calcium 51 plasma HCV RNA 51 non valvular atrial 51 mg tid 51 fasting triglycerides 51 placebo p = 51 mediated dilation 51 HCTZ 51 angiotensin converting enzyme inhibitor 51 sweat chloride 51 achieved statistical significance 51 mineral density 51 β blocker 51 Hb A1c 51 hypokalemia 51 troponin T 51 antiretroviral naive 51 cells mcL 51 Ishak fibrosis score 51 5mg/kg 51 serum selenium 51 ACTEMRA TM 51 metoprolol tartrate 51 Non inferiority 51 diuretics beta blockers 51 hsCRP 51 Engerix B 51 Proteinuria 51 histological subtype 51 trough FEV1 51 TLUS 51 CI #.#-#.# [002] 51 IDDM 51 carotid intima media 51 ATV RTV 51 antibody titer 51 systolic hypertension 51 moderate hepatic impairment 51 spirometric 51 nonresponders 51 calculated creatinine clearance 51 tolvaptan 51 plus OBT 51 Platelet Inhibition 51 unresectable HCC 51 CI #.#-#.# [001] 51 AUC0 51 Oral Fingolimod 51 Glatiramer Acetate 51 hypertensive patients 51 Postprandial 51 ventricular mass 51 carotid IMT 51 mercury mmHg 51 aminotransferase ALT 51 Hypercholesterolemia 51 confidence interval CI 51 ascending dose 51 antiretroviral naïve 51 mL kg 51 normothermic 51 MMSE scores 51 Protease Inhibitors 51 Placebo controlled 51 intraocular pressure IOP 51 isoprostane 51 A1C levels 51 myocardial uptake 51 QD dosing 51 severe neutropenia 51 euthyroid 51 transaminase levels 51 paresthesias 51 MMSE score 51 rheumatoid factor 51 annualized relapse 51 uL 51 Atacand 51 LDL Cholesterol 51 fosamprenavir 51 oral antidiabetic medication 51 micromoles 51 amoxicillin clavulanate 51 #mg QD [002] 51 μg d 51 orthostatic hypotension 51 prostate cancer CaP 51 mean baseline HbA1c 51 antihypertensive agents 51 p = .# [002] 51 lowering uric acid 51 lanthanum carbonate 51 min -1 51 SHBG levels 51 hypogonadal 51 glyburide 51 beta carotene supplementation 51 baseline serum bilirubin 51 Viread Emtriva Sustiva 51 Prehypertension 51 drank caffeinated 51 gadolinium enhancing lesions 51 ventricular tachyarrhythmia 51 mg QD 50 mmol L. 50 triglyceride levels 50 tryptase 50 evaluable subjects 50 -#.# ± [001] 50 fasting blood glucose 50 μg g 50 metabolite concentrations 50 hemoglobin concentrations 50 μmol l 50 glucose intolerant 50 perioperatively 50 glycoprotein IIb IIIa inhibitors 50 = #.#-#.# 50 Patients Treated With 50 OGTT 50 GERD symptom 50 #μg [001] 50 SSRI SNRI 50 ST Segment Elevation 50 Tiotropium 50 mCi kg 50 fatigue asthenia 50 Ischemic 50 mL min 50 overt nephropathy 50 XIENCE V vs. 50 ertapenem 50 n = 50 Univariate analysis 50 hemoglobin hematocrit 50 detrusor 50 paroxysmal AF 50 LANTUS R 50 mU L 50 Double Blind Randomized 50 isolated systolic hypertension 50 transaminase elevations 50 Serum concentrations 50 leukocytosis 50 nonadherent 50 interquartile range 50 patients undergoing CABG 50 RBC folate 50 hydroxyvitamin D levels 50 virologic failure 50 onset diabetes mellitus 50 certolizumab 50 ANCOVA 50 per deciliter mg 50 Diastolic pressure 50 #OHD 50 LV dysfunction 50 melphalan prednisone 50 infarction NSTEMI 50 cirrhotic 50 UGT#A# * 50 nmol L 50 Pred Forte 50 postintervention 50 PTH analog 50 TEAEs 50 diastolic pressure 50 severe renal insufficiency 50 hemoglobin Hb 50 #.#g/day 50 mU 50 randomized multicenter trial 50 osteopenic 50 Septic Shock 50 del 5q MDS 50 #mg/m# [002] 50 triglyceride concentration 50 periprocedural MI 50 QTcF 50 macroalbuminuria 50 Scandinavian Cardiac Outcomes 50 urinary albumin excretion 50 serum LDL cholesterol 50 KRAS mutations occur 50 oxidised LDL 50 cholestorol 50 Creatinine 50 HDL2 50 orthostatic 50 underwent CABG 50 serum lipid 50 IIIa inhibitor 50 undergone radical prostatectomy 50 trials RCTs 50 Secondary endpoints 50 #q# deletion syndrome 50 hyperemia 50 #.#mmol l [002] 50 % CI #.#-#.# [004] 50 obese postmenopausal 50 Lipid Lowering Treatment 50 #mg BID [002] 50 VLDL cholesterol 50 nonfatal myocardial infarction MI 50 salmeterol fluticasone propionate 50 glimepiride 50 cGy 50 microvascular complications 50 test OGTT 50 SORT OUT III 50 PsA 50 Psoriasis Area 50 Triglyceride 50 Treated Patients 50 noncardiovascular mortality 50 mIU mL 50 neurodevelopmental impairment 50 beta blocker therapy 50 pharmacokinetic parameters 50 platelet inhibition 50 stage IIIB 50 plus dexamethasone 50 atorvastatin #mg 50 fluoxetine paroxetine 50 rs# [002] 50 SNP rs# [001] 50 left ventricular diastolic 50 residual platelet reactivity 50 arteriolar 50 Comorbidities 50 mineral density BMD 50 glycemia 50 limiting generalizability 50 PANSS total 50 Renal Cell Carcinoma 50 serum phosphate 50 nonmetastatic 50 zonisamide SR 50 phonophobia 50 preserved ejection fraction 50 ventricular repolarization 50 hemoglobin A1C 50 Juvenile Idiopathic Arthritis 50 CRESTOR #mg 50 mg Lucentis 50 intratympanic 50 ventricular ejection fraction 50 lipid abnormalities 50 TC HDL 50 ml min 50 refractory NSCLC 50 HBeAg negative 50 Blood Pressure Drugs 50 drug eluting stent implantation 50 Procardia 50 Statistically Significant 50 Triglycerides 50 Inhaled Corticosteroids 50 Monitoring ABPM 50 docetaxel prednisone 50 nadroparin 50 seminomas 50 μg ml 50 DAS# remission 50 homozygotes 50 Patients Undergoing 50 TDF FTC 50 TAXUS Express Stent 50 WARNINGS Myopathy Rhabdomyolysis 50 complete cytogenetic response 50 Pain Intensity 50 placebo fluoxetine 50 cardiovascular mortality 50 induced sputum 50 P ≤ 50 #mg BID [001] 50 progression TTP 50 oxygen desaturation 50 eNO 50 uncontrolled hypertension 50 LVSD 49 Hematologic 49 % CI #.#-#.# [001] 49 serum aminotransferase levels 49 DAS# [002] 49 Hazard Ratio HR 49 Hyperlipidemia 49 pegylated interferon alfa 2b 49 Median PFS 49 deletion 5q 49 thyroid stimulating hormone 49 ml kg 49 arterial stiffening 49 ADAS Cog 49 A1c levels 49 CIN3 49 lipid levels 49 Somnolence 49 angiotensin receptor blockers ARBs 49 HBeAg positive 49 Viral load 49 HI titers 49 Cotinine 49 recurrent VTE 49 prostate carcinoma 49 tertile 49 stable angina 49 Paclitaxel Carboplatin 49 corrected QT interval 49 cortisol concentrations 49 univariate analyzes 49 immunostaining 49 spine BMD 49 triglycerides ≥ 49 fractional anisotropy 49 Ejection Fraction 49 nanomoles per 49 postprocedure 49 rs# [003] 49 CYPHER Stent 49 malignancy HCM 49 HMG CoA reductase inhibitor 49 serum clusterin levels 49 elevated triglycerides 49 cardiovascular morbidity 49 platelet reactivity 49 PANSS scores 49 LEXIVA r 49 IOP lowering 49 resistant hypertension 49 clinically meaningful improvements 49 fructosamine 49 ± SD 49 oral allopurinol 49 Cardiac Resynchronization 49 hormone receptor status 49 ± SEM 49 Postoperative 49 Darapladib 49 lipid lowering drugs 49 p ≤ 49 nonvertebral fractures 49 postdose 49 plasma leptin 49 Scale EDSS score 49 elevated triglyceride levels 49 systolic pressure 49 IPSS 49 mcg albinterferon alfa 2b 49 angina chest 49 iPTH 49 #mg/m# [001] 49 glucose triglycerides 49 follicular phase 49 serum cholesterol 49 Shows Efficacy 49 OADs 49 Improves Outcomes 49 Polyp Prevention Trial 49 NYHA Class II 49 hs CRP 49 LDL HDL 49 microalbumin 49 HIV uninfected 49 Asymptomatic 49 TMC# r 49 sweating nausea 49 systemic embolism 49 periprocedural 49 HLA DRB1 * 49 milliliter ng ml 49 allopurinol 49 serum triglyceride levels 49 thromboembolic 49 Platelet counts 49 urate lowering therapy 49 Left Ventricular Ejection Fraction 49 sulphonylurea 49 elevated blood glucose 49 nonfatal myocardial infarction 49 histologic subtype 49 postprandial blood glucose 49 nmol l 49 nonfatal stroke 49 hematologic parameters 49 thyroglobulin 49 antihypertensive drugs 49 Increased Mortality 49 serum GGT 49 serum calcium levels 49 mol L 49 multicenter randomized controlled 49 telomere lengths 49 mg ustekinumab 49 ECOG PS 49 microangiopathy 49 ng ml 49 ARCOXIA 49 subcutaneous insulin 49 colorectal neoplasms 49 C reactive protein 49 FOLFIRI alone 49 BMI z 49 Study ARIC 49 nM 49 Decitabine 49 serum sodium levels 49 Acute Pancreatitis 49 NOLVADEX 49 ALT elevations 49 CsA 49 metabolic parameters 49 Lucentis monotherapy 49 tumor histology 49 methacholine challenge 49 SBM frequency 49 undetectable HBV DNA 49 c reactive protein 49 severe periodontitis 49 dactylitis 49 ARB telmisartan 49 YMRS 49 serum albumin 49 Skin sterol 49 elevated IOP 49 Fracture Risk 49 Renal Cell Cancer 49 baseline CD4